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Abstract 
Purpose: To investigate effects of triptolide on colon cancer cell growth and its capacity to prevent 
tumor development in an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model of colon 
cancer.  
Methods: HCT116 cell viability and migration potential were assessed. Control and AOM/DSS-treated 
mice (with and without triptolide) were analyzed for tumor development. The animals were divided into 
five groups (n = 5). Normal control group was given saline, animals in the untreated control group 
received AOM and DSS while animals in the treatment groups received 10, 50 and 100 mg/kg doses of 
triptolide intraperitoneally alternately for 2 months after AOM and DSS injection. 
Results: Triptolide enhanced nuclear material condensation, significantly (p < 0.05) increased the levels 
of cleaved poly (ADP-ribose) polymerase, reduced the levels of pro-caspase-3 and pro-caspase-8 in 
HCT116 cells. Triptolide also significantly (p < 0.05) decreased the expression of pIκBα, activated 
peroxisome proliferator-activated receptor γ, and markedly reduced the activity of both 
metalloproteinase-2 and metalloproteinase-9. Treatment of AOM/DSS mice with triptolide significantly 
reduced adenocarcinoma multiplicity compared to the control group. 
Conclusion: Triptolide administration suppresses growth of HCT116 cells and colon cancer 
development in mice by inhibiting inflammatory responses. Therefore, triptolide has potentials to be 
developed for colon cancer therapy. 
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Colon cancer is one of the most commonly 
diagnosed causes of premature mortality in 
people of developed countries [1-3]. Tumors 
present in the lining of the colon are the main 
cause of deaths associated with cancer in the 
United States [4]. Adoption of westernized 
dietary patterns has greatly increased the 
incidence of colon cancer in Asian people [5].  
 
Cellular apoptosis maintains homeostasis in 
living organisms by destroying unwanted cells via 
both extrinsic and intrinsic pathways [6]. In the 
extrinsic apoptotic pathway, receptors on the cell 
surface activate caspase-8 [7], whereas in the 
intrinsic apoptotic pathway, various types of 
cellular stimuli change the expression levels of 
members of the Bcl-2 family, leading to the 
release of cytochrome c [7].  
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The process of cellular apoptosis is evident by 
changes in cellular morphology, such as altered 
membrane shape, cell shrinkage, lower 
mitochondrial membrane potential, nuclear 
material condensation, and fragmentation of 
double-stranded DNA [8,9]. In various types of 
carcinomas, such as of the colon, liver, and 
pancreas, the expression levels of peroxisome 
proliferator-activated receptor γ (PPARγ) 
increase [10]. Studies have shown that PPARγ is 
associated with the regulation of various 
processes associated with inflammation [11]. The 
inflammatory responses induced by nuclear 
factor-κB (NF-κB) are suppressed by PPARγ and 
its upstream activators. It has been reported that 
PPARγ activation, after exposure to punicic acid, 
inhibits the inflammation of intestinal tissues in 
mouse [12]. The expression of genes associated 
with the inhibition of inflammation is suppressed 
by PPARγ by the targeting of various factors 
such as NF-κB, p65, and p50 [13]. 
 
Natural products isolated during phytochemical 
investigations have demonstrated promising 
potential in inhibiting tumor development and 
progression by stimulating cellular apoptosis 
[14,15]. For example, triptolide, which was 
isolated during the phytochemical investigation of 
Tripterygium wilfordii Hook F, is a complex 
diterpenoid molecule [16-18]. Biological 
investigations of triptolide have revealed its 
potential as a suppressor of the immune system, 
an anticancer agent, and a contraceptive [16-18]. 
Triptolide treatment of cancer cells induces 
apoptosis via cytochrome c release, damages 
mitochondria, and suppresses antiapoptotic 
protein expression [19].  
 
In the present study, the growth inhibitory effects 
of triptolide on colon cancer cells and on tumor 
development in an azoxymethane/dextran sulfate 
sodium (AOM/DSS) mouse model were 
investigated. The results demonstrate that 
triptolide treatment of colon cancer cells reduces 
viability, induces apoptosis, and suppresses 






Triptolide obtained from Sigma-Aldrich Co. (St. 
Louis, MO) was dissolved in dimethylsulfoxide to 
prepare the stock solution. Various 
concentrations of triptolide were prepared at the 
time of use in experiment. A colonic carcinogen 
azoxymethane (AOM) was purchased from 
Sigma-Aldrich. Dextran sulfate sodium (DSS) 
with a molecular weight of 36, 000 - 50, 000 (cat. 
no. 160110) was purchased from MP 




HCT116 colon cancer cells were purchased from 
Shanghai Institute of Biochemistry and Cellular 
Biology Chinese Academy of Sciences 
(Shanghai, China). The cells were cultures in 
Dulbecco's modified Eagle's medium (DMEM; 
Gibco Life Technologies, Carlsbad, CA, USA) 
containing 10 % fetal bovine serum. Antibiotics 
such as penicillin (100 U/ml) and streptomycin 
(100 U/ml) were also added to the medium. 
Culture of cells was performed at 37 oC in an 
incubator with humidified atmosphere of 5 % CO2 




HCT116 and DLD-1 cells after culture in 
Dulbecco's modified Eagle's medium (DMEM; 
Gibco Life Technologies, Carlsbad, CA, USA) for 
24 h were incubated with various doses of 
triptolide for 72 h. MTT (3-(4, 5-dimethylthiazol2-
yl)-2, 5-diphenyltetrazolium bromide, 5 mg/ml) 20 
µl was put into each of the well of 96-well plates 
and then incubation was continued for 4 h more. 
Following decantation of medium 150 µl of Write 
in full the first time with the abbreviation in 
brackets was put into each well of the plate. 
Absorbance was recorded for each well three 
times by multi-well reader at a wavelength of 490 




HCT116 cells (2 x 105 cells per ml) after 
incubation with various doses of triptolide were 
collected, washed with PBS three times and then 
treated with binding buffer. Then 5 µl each of 
annexin-V-fluorescein isothiocyanate (FITC) and 
propidium iodide (PI) were added to cells and the 
cells were subjected to 15 min incubation under 
dark atmosphere at room temperature. 
FACScalibur Flow Cytometer (BD Biosciences, 
San Jose, CA, USA) was used for the analysis of 
induction of apoptotic changes in the cells. 
 
Western blot analysis 
 
HCT116 cells were subjected to incubation with 
various doses of triptolide for 72 h. The cells 
were then collected and lysed on treatment with 
lysis buffer followed by measurement of protein 
concentration in the supernatant (Pierce, 
Rockford, IL). The protein separation was 
achieved using 10 % sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
Separated proteins were transferred onto the 
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nitrocellulose membrane and subsequently 
incubated with primary antibodies against NF-κB, 
PPARγ, pIκBα, iNOS, p50, p65, MMP-2, MMP-9 
and β-actin (all Wuhan Boster Biological 
Technology, Ltd., Wuhan, China; 1: 1, 000). After 
incubation the membranes were washed and 
then incubated with horseradish peroxidase-
conjugated secondary antibodies (Wuhan Boster 
Biological Technology, Ltd.; 1: 10, 000). The 
complexes formed by interaction of antigen and 
antibody were analyzed using the enhanced 
chemiluminescence (ECL) detection system (GE 
Healthcare Biosciences, Pittsburgh, PA).  
 
Analysis of migration potential 
 
For the measurement of HCT116 cell migration 
24-well Boyden chamber (Corning, Tewksbury, 
MA) was used. Into the inserts of upper 
compartment of the Trans well chamber HCT116 
cells were put at a density of 5 x 105 cells per 100 
µl in the medium devoid of serum. The lower 
chamber contained 600 µl RPMI 1640 
supplemented with 10 % FBS. Migration of the 
cells was allowed for 72 h under conditions of 37 
oC temperature and in an atmosphere of 5 % 
CO2. Gentle rubbing was performed to remove 
the cells that did not migrate using cotton swab. 
The migrated cells on the lower surface PBS 
washed and then fixed using methyl alcohol. The 
cells were then subjected to crystal violet staining 
followed by measurement of optical density three 




Institute of Cancer Research strain (ICR) of mice 
twenty five in number and seven week old were 
supplied by the Experimental Animal Centre of 
Zhejiang University (Hangzhou, China). In the 
animal facility center housing was done under 
diurnal lighting conditions with 12 h dark and light 
cycles and were provided free access to water 
and food. The temperature in the animal facility 
centre was maintained ~25 ˚C and humidity 
adjusted to (55 ± 10 %). The animals were 
acclimatized to laboratory atmosphere for seven 




The protocol for the study on animals was appro- 
ved by the Committee on the Ethics of Animal 
Experiments of the Affiliated Hospital of 
Academy of Military Medical Sciences (no. 
MMSA-102/2014). The study was performed 
according to the guidelines for Ethical Conduct in 
the Care and Use of Non-human Animals in 





An aqueous solution of dextran sulfate sodium 
(1.5 % w/v) was prepared for inducing colitis in. 
The animals were divided into five groups of five 
mice each. The normal control group were given 
saline, animals in the untreated control group 
received AOM and DSS whereas animals in the 
treatment groups received 10, 50 and 100 mg/kg 
doses of triptolide intraperitoneally alternately for 
2 months after AOM and DSS injection. After 
completion of treatment (2 months) the animals 
were sacrificed using sodium pentobarbital 
anesthesia to extract colon. The colon tissues 
were subjected to histopathological analysis after 




The data obtained were processed using 
Statistical Package for Social Sciences for 
Windows, version 17.0 (SPSS, Inc, Chicago, IL, 
USA). Analysis of the data was performed using 
monofactorial analysis of variance. The data are 
presented as mean ± standard deviation (SD). P 




Viability of HCT116 cells is inhibited by 
triptolide 
 
Triptolide decreased the viability of HCT116 and 
DLD-1 cells in a dose-dependent manner. At 
doses of 10, 50, 100, 150, and 200 µM, triptolide 
decreased HCT116 cell viability by 8, 27, 53, 74, 
and 89 %, respectively, after 72 h of treatment 
(Figure 1). Additionally, the viability of DLD-1 
cells was decreased by 11, 31, 49, 68, and 83 % 
after the addition of 10, 50, 100, 150, and 200 




Figure 1: HCT116 and DLD-1 cell viability is reduced 
by triptolide. Changes in cell viability were determined 
using an MTT assay and compared to control cultures. 
Measurements were made in triplicate. *p < 0.05 and 
**p < 0.05 compared with control cultures 
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Figure 2: Triptolide induces apoptosis in HCT116 cells. (A) Cells were analyzed at a magnification of ×320 using 
a Hoechst 33342 stain and fluorescent microscope. (B) Western blot assay results show the expression levels of 
cleaved PARP, pro-caspase-3, and pro-caspase-8. β-actin was used as a loading control 
 
Triptolide stimulates apoptosis in HCT116 
cells  
 
Triptolide induced apoptotic changes in HCT116 
cells. Increasing the triptolide dose from 10 to 
200 µM increased the population of HCT116 
cells that underwent nuclear material 
condensation (from 6 to 72 %) after 72 h of 
treatment (Figure 2A). Western blot analysis 
showed a significant increase in the level of 
cleaved PARP and a reduction in the expression 
levels of pro-caspase-3 and pro-caspase-8 in 
HCT116 cells after the addition of triptolide 
(Figure 2B). 
 
Triptolide reduces NF-κB activity in HCT116 
cells 
 
The expression levels of NF-κB were analyzed in 
HCT116 cells by western blot analysis. After 72 h 
incubation with 200 µM triptolide, the expression 
of pIκBα was significantly decreased, and 
PPARγ activity was increased (Figure 3). No 
significant increase was observed in the activity 
of PPARγ at either the 10- or 50-µM doses of 
triptolide. The levels of pIκBα, inducible nitric 
oxide synthetase (iNOS), p50, and p65 were also 




Figure 3: Triptolide treatment of HCT116 cells 
activates PPARγ and downregulates pIκBα. Levels of 
PPARγ, pIκBα, iNOS, p50, and p65 were measured by 
western blot analysis. β-actin was used as a loading 
control 
 
Migration of HCT116 cells is reduced by 
triptolide 
 
Triptolide reduced the migratory potential of HCT 
116 cells after 72 h (Figure 4A). Compared to 
control cell cultures, the migratory potential of 
HCT116 cells was reduced significantly after a 
72-h incubation with 100 µM triptolide. In 
addition, HCT116 cells treated with 100 µM 
triptolide for 72 h showed a marked reduction in 
the activity of both metalloproteinase-2 and 
metalloproteinase-9 (Figure 4B). 
 
Tumor growth is inhibited by triptolide in an 
AOM/DSS mouse model 
 
Untreated control AOM/DSS mice showed 
markedly high tissue inflammation, as shown in 
hematoxylin- and eosin-stained sections. On the 
other hand, treatment of AOM/DSS mice with 
100 µM triptolide significantly prevented tissue 
inflammation (Figure 5). The incidence of tumors 
in the untreated control group was significantly 
higher than in the triptolide-treated groups. 
Adenocarcinoma multiplicity in the untreated 
control group was 3.35 ± 0.98, which was 
reduced to 2.16 ± 0.56, 1.87 ± 0.46, and 0.43 ± 
0.23, respectively, in mice treated with 10, 50, 




The current study demonstrates the inhibitory 
effects of triptolide on colon cancer cell growth 
and on tumor growth in an AOM/DSS mice 
model. Triptolide reduced the viability of HCT116 
cells via apoptotic cell death and prevented 
tumor growth in mice. Cell death can occur via 
an apoptotic or non-apoptotic pathway. 
Apoptosis, or programmed cell death, maintains 
homeostasis via either an intrinsic or extrinsic 
pathway [21]. 
 
Our study revealed that triptolide reduced 
HCT116 cell viability through an apoptotic 
pathway, which was evident by nuclear material 
condensation. In addition, triptolide promoted the 
expression of cleaved PARP and decreased the 
expression of pro-caspase-3 and pro-caspase-8 
in HCT116 cells. It is known that agonists of 
PPARγ inhibit colorectal tumor progression via 
the upregulation of genes associated with tumor 
suppression [22]. 
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Figure 4: Triptolide reduces migratory potential of HCT116 cells. (A) Cell cultures were scratched with a pipette 
tip and incubated for 72 h with either triptolide or solvent (control). The movement of cells into the wounded area 
was monitored, and photographs were taken. (B) Various doses of triptolide were then added, and the cells were 




Figure 5: Triptolide treatment of AOM/DSS mice prevents tumor growth. Mice were treated with 10, 50, and 100 
µM triptolide for 2 months and then sacrificed for analysis of tissue inflammation and tumor incidence 
 
Such agonists are thus considered to be of great 
significance for the development of effective 
chemotherapeutic strategies for colon cancer. 
Active PPARγ inhibits cellular inflammatory 
processes by targeting gene transcription. 
Expression of various factors, such as iNOS, 
cyclooxygenase-2, etc., is associated with the 
upregulation of inflammatory processes that are 
regulated by NF-κB [23]. Colon cancer patients 
are reported to have high levels of active NF-κB, 
which stimulate tumor progression [24]. Results 
from the present study show that triptolide 
enhances PPARγ levels and reduces iNOS 
levels in HCT116 cells. Additionally, 
metalloproteinases have been shown to play 
important roles in promoting tumor migration and 
invasive potential [25].  
 
In HCT116 cells, triptolide increases the 
expression levels of molecules that promote 
tumor migration and invasion. The levels of both 
metalloproteinase-2 and metalloproteinase-9 
were markedly increased after incubation of 
HCT116 cells with triptolide. A previous study 
demonstrated that active PPARγ caused the 
inhibition of alimentary canal inflammation; thus, 
its expression is of significance for the treatment 
of colon cancer [26]. Our study demonstrated 
that triptolide treatment of AOM/DSS mice 
significantly prevented colon tissue inflammation. 
Moreover, tumor incidence was significantly 





The findings of this study show that triptolide 
reduces the viability of colon cancer cells via the 
induction of apoptosis and prevents tumor 
metastasis in vivo. Therefore, triptolide should be 
further evaluated as an effective chemothe-
rapeutic agent for colon cancer. 
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